Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dactolisib - Novartis/Adicet Bio

Drug Profile

Dactolisib - Novartis/Adicet Bio

Alternative Names: BEZ-235; Dactolisib-tosylate; NVP-BEZ-235; NVP-BEZ235-ANA; NVP-BEZ235-NX; RTB-101

Latest Information Update: 28 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Adicet Bio; Brown University Medical School; Memorial Sloan-Kettering Cancer Center; Novartis
  • Class 3-ring heterocyclic compounds; Acetonitriles; Anti-infectives; Antineoplastics; Antiparkinsonians; Antivirals; Benzenesulfonates; Heart failure therapies; Imidazoles; Nitriles; Quinolines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; 3 phosphoinositide dependent protein kinase 1 inhibitors; Apoptosis stimulants; Immunostimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Respiratory tract infections
  • Phase II COVID 2019 infections; Influenza virus infections
  • Phase I/II Parkinson's disease
  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Heart failure; Urinary tract infections
  • Discontinued Breast cancer; Glioblastoma; Haematological malignancies; Non-small cell lung cancer; Pancreatic cancer; Perivascular epithelioid cell tumours; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for phase-I development in Heart-failure(Combination therapy) in USA (PO)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Parkinson's-disease(Combination therapy) in USA (PO, Capsule)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Urinary-tract-infections in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top